Chemoresistant myeloma: Phase II clinical study with low-dose thalidomide plus high-dose dexamethasone

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 5, 2004, Pages 90-93

  Bernardeschi, Paolo ^a   Dentico, P ^a   Rossi, S ^a   Fiorentini, G ^a   Giustarini, G ^a   Montenora, I ^a   Turano, E ^a  

^a SAN GIUSEPPE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Dexamethasone; Myeloma; Thalidomide

Indexed keywords

ALENDRONIC ACID; DEXAMETHASONE; ERYTHROPOIETIN; THALIDOMIDE; ZOLEDRONIC ACID;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIZZINESS; DRUG MEGADOSE; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LOW DRUG DOSE; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; SEDATION; SURVIVAL TIME; THROMBOEMBOLISM; TREMOR;

EID: 11144235824     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1120009x.2004.11782395     Document Type: Conference Paper

References (10)

1. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med Volume 1999; 341:1565-1571.
2. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients. Report of the Intergroupe Francophone du Myélome (IFM). Hematol J 2002; 3:185-92.
3. Osman K, Comenzo R, Rajkumar S. V Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma N Engl J Med 2001; 344:1951-1952.
4. Raijkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 2000; 343:972-73.
5. Morgan AE, Smith WK, Levenson JL. Reversible dementia due to thalidomide therapy for multiple myeloma. N Engl J Med 2003; 348:1821-1822.
6. Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-9
7. Bernardeschi P, Dentico P, Rossi S, Fiorentini G, Turano E. Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eigth patients previously treated with multiple myeloma. J Exp Clin Cancer Res 2003; 22:129-33 Supplement.
8. Cavenagh JD, for the British Committee for standards in Haematology/Oncology Task Force. Guidelines. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120:18-26.
9. Kropff MH, Inning G, Mitterer M, et al. Hyperfractinated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. Blood 2000; 96:168a.
10. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89:826-831.